Patents by Inventor Walter Owens

Walter Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092128
    Abstract: An articulating tire valve install-removal tool and related methods for use. The articulating tire valve install-removal tool has a body comprising an outer perimeter, an inner recess, a threaded member, a linkage, and a contact member. The articulating tire valve install-removal tool components are connected to each other and secured within the body so one or more components can rotate around one or more axes. Together these components facilitate in the valve being installed and removed perpendicular or generally perpendicular to the valve hole on the wheel. The articulating tire valve stem tool includes a linkage assembly that is attached to the body to facilitate in ensuring the valve is installed and removed with the valve perpendicular to the valve hole in the wheel rim.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 21, 2024
    Inventors: George Walter Tatum, Graham Kendall Snyder, Mackenzie John Owen Snyder, Scott R. Lakin, Kristopher Jon Soderstrom, Brian Patrick Rigney
  • Publication number: 20110065783
    Abstract: Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6?difluoro-, 4-hydroxy-5-phenol-6,6?difluoro-, and 4-hydroxy-8-pheno-6,6?difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 20, 2010
    Publication date: March 17, 2011
    Inventors: John P. O'Donnell, Walter Owens, Joseph Duncan, Andrew Shaw, Jinn Wu
  • Publication number: 20070014733
    Abstract: Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6?difluoro-, 4-hydroxy-5-phenol-6,6?difluoro-, and 4-hydroxy-8-pheno-6,6?difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 30, 2006
    Publication date: January 18, 2007
    Inventors: John O'Donnell, Walter Owens, Joseph Duncan, Andrew Shaw, Jinn Wu
  • Publication number: 20070014734
    Abstract: This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.
    Type: Application
    Filed: January 30, 2006
    Publication date: January 18, 2007
    Inventors: John O'Donnell, Walter Owens, Joseph Duncan, Andrew Shaw